产品中心
-
产品货号
产品名称
规格
销售价
会员价
货期
产地
订购
-
CH76
Recombinant Human OASL/2'-5'-oligoadenylate synthase-like protein
10ug
1400
1260
现货
国产
-
CH76
Recombinant Human OASL/2'-5'-oligoadenylate synthase-like protein
50ug
3600
3240
现货
国产
-
CH76
Recombinant Human OASL/2'-5'-oligoadenylate synthase-like protein
500ug
12320
11088
现货
国产
-
CH76
Recombinant Human OASL/2'-5'-oligoadenylate synthase-like protein
1mg
17600
15840
现货
国产
- 产品简介
- 使用说明
- 相关产品
- 参考文献
- 购买咨询
Catalog# CH76 Source E.coli Description Recombinant Human OASL is produced with our E. coli expression system. The target protein is expressed with sequence (Met1-His100) of Human OASL fused with a polyhistidine tag at the C-terminus. Names 2'-5'-oligoadenylate synthase-like protein,2'-5'-OAS-related protein,2'-5'-OAS-RP,59 kDa 2'-5'-oligoadenylate synthase-like protein,Thyroid receptor-interacting protein 14,TR-interacting protein 14,TRIP-14,p59OASL,OASL,TRIP14 Accession # Q15646 Formulation Supplied as a 0.2 μm filtered solution of 20mM PB,150mM NaCl,pH7.4 Shipping The product is shipped on dry ice/ice packs. Storage Store at < -20°C, stable for 6 months after receipt.
Please minimize freeze-thaw cycles.Purity Greater than 95% as determined by SEC-HPLC and reducing SDS-PAGE. Endotoxin Less than 0.1 ng/µg (1 IEU/µg). Amino Acid Sequence MALMQELYSTPASRLDSFVAQWLQPHREWKEEVLDAVRTVEEFLRQEHFQGKRGLDQDVRVLKVV KVGSFGNGTVLRSTREVELVAFLSCFHSFQEAAKHLEHHHHHHBackground 2'-5'-oligoadenylate synthase-like protein (OASL) contains 2 ubiquitin-like domains, and belongs to the 2-5A synthase family. The ubiquitin-like domains are essential for its antiviral activity. OASL can be induced by type I interferon (IFN) and viruses, and expressed in most tissues such as primary blood Leukocytes and other hematopoietic system tissues, colon, stomach and to some extent in testis. OASL can specifically interacts with the ligand binding domain of the thyroid receptor (TR) without the presence of thyroid hormone. It does not have 2'-5'-OAS activity, but can bind double-stranded RNA. It also displays antiviral activity against encephalomyocarditis virus (EMCV) and hepatitis C virus (HCV) via an alternative antiviral pathway independent of RNase L.